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eart Disease Leaves its Mark
roteomics-Based Biosignatures
n Acute Coronary Syndromes*
. Robb MacLellan, MD, FACC,
eipei Ping, PHD, Thomas Vondriska, PHD
os Angeles, California
n 1990, the Human Genome Project officially began with
goal to sequence the entire human genome in 15 years.
ith progressive technologic advancements and the contri-
utions made by international groups and private industry,
draft of the human genome was published in 2001, well
head of expectations (1,2). This accomplishment has had a
rofound impact on the scientific, medical, and pharmaceu-
ical communities and ushered in a new era of diagnostic
nd therapeutic discovery. The Human Genome Project
dentified 32,000 distinct genes in humans; however,
here are many more proteins than genes due to the
ost-translational modifications of proteins, making the
uman proteome much larger and more complex.
roteomics—the comprehensive and systematic study of
lobal alterations in protein expression in normal or diseased
iologic samples—has emerged as a novel field of study to
ddress the technical challenges posed by this complexity.
See page 1578
The sheer number of proteins and post-translational
odifications, as well as the dynamic nature of protein
xpression, in contrast to the relatively stable genome,
akes proteomics very challenging. It has only been with
echnologic advances in the last decade that the tools have
ecome available to begin to apply proteomic methodology
o clinical medicine. These advances include enhanced
rotein separation and staining techniques, allowing iden-
ification of less abundant proteins and improvements in
ass spectrometry (MS), which allow unequivocal identifi-
ation of proteins of interest, rather than simply following
hanges in expression patterns. It is exactly these complex-
ties in proteomics that underlie the high expectations of
his technology to deliver improved human health care, as
early all disease states, even those with genetic origin,
ltimately involve malfunctioning, modified, and/or absent
roteins. Accordingly, proteins are the final targets of most
rugs. Thus, a greater understanding of protein dynamics
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiovascular Research Laboratory, Departments of Physiology andi
edicine, David Geffen School of Medicine at University of California at Los
ngeles, Los Angeles, California.e.g., turnover, structure, and activity) will facilitate the
esign of more accurate and efficacious drugs. In clinical
edicine, integration of proteomics-based approaches into
tandard care has at least four potential advances over
urrent approaches (3–5): 1) protein biomarkers of cardio-
ascular disease identified by proteomics could lead to
arlier and more accurate detection of cardiovascular syn-
romes; 2) proteomics-derived information may comple-
ent existing diagnostic tools in the risk stratification of
atients; 3) proteomic information gathered on a patient-
y-patient basis will likely facilitate individualized treat-
ent; and 4) proteomic tools and information applied at
arious stages of treatment will allow for real-time assess-
ent of treatment efficacy and will enhance the ability to
odify future therapy options.
The methodologic advancements in the field of proteom-
cs, as described already, now allow the analysis of complex
uid or tissue samples under clinically relevant conditions
nd protein profiling to study specific diseases or biologic
rocesses. The study by Matteos-Cáceres et al. (6) in this
ssue of Journal utilizes a proteomics approach to describe
ovel biosignatures associated with acute myocardial infarc-
ion (AMI) and unstable angina (UA). Each year, eight
illion patients with chest pain are evaluated in emergency
epartments in the U.S., and nearly one-half of these
ndividuals are admitted to inpatient units for further
valuation and treatment. Despite advances in the diagnosis
f acute coronary syndrome (ACS), only a minority of these
atients will ultimately be found to truly be suffering from a
ardiac condition (7). Cardiac biomarkers, such as cardiac
roponins, brain natriuretic peptide (BNP), and high-
ensitivity C-reactive protein (hs-CRP), have played an
ncreasingly important role in triaging these patients, as well
s guiding therapy and determining the subsequent risk of
dverse events (8). However, further progress is needed to
haracterize markers that better identify specific subsets of
ffected patients, detect underlying pathology, and predict
he response to subsequent therapy.
The majority of proteomic investigations in recent years
ave taken one of two broad approaches: expression pro-
eomics, in which qualitative and quantitative alterations in
roteins are catalogued for a given clinical condition; and
unctional proteomics, in which additional attributes of
ultiple proteins are studied and a mechanistic link be-
ween proteome change and disease phenotype is sought.
nvestigations like that by Matteos-Cáceres et al. (6) com-
ine these two approaches and illustrate the power of a
ocused proteomic investigation to target a subset, or sub-
roteome, of proteins potentially containing diagnostic and
tiologic information related to a disease phenotype. In
heir study, Matteos-Cáceres et al. (6) employed two-
imensional electrophoresis and matrix-assisted laser de-
orption ionization time of flight (MALDI-TOF) MS—
ow standard techniques in proteomics—to display anddentify proteins in plasma from patients with either UA or
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October 19, 2004:1584–6 Editorial CommentMI. The authors initially identified proteins by peptide
ass fingerprinting in the single MS mode. Although this
ethod is adequate to identify proteins under some condi-
ions (such as after two-dimensional electrophoresis), pep-
ide mass fingerprinting is not a robust technique for
nalysis of complex mixtures (i.e., more than a few proteins)
nd does not provide optimal accuracy for protein identifi-
ation. In some cases, however, the investigators employed
ALDI-TOF-TOF analyses to identify proteins when
ingle MS analyses proved equivocal. This tandem MS
pproach offers among the highest sensitivity for protein
dentification that is currently available and increased the
onfidence in some of the identifications made by the
uthors. The importance of this technique should not be
verlooked, as it highlights an aspect of proteomics that
acilitates the understanding of disease pathogenesis in
ddition to yielding biomarkers. As mentioned earlier, even
he gel pattern (or MS patterns, as used by other investiga-
ors [4]) can serve as a biosignature of disease phenotype.
owever, the ability to reap peptide sequence information
which can only be done with tandem MS experiments)
llows for the confident identification of proteins and for the
apping of post-translational modifications and degrada-
ion products. These two changes, not obvious from
enomic information, can be clearly characterized only with
S/MS approaches, using electrospray or MALDI (as in
he Matteos-Cáceres et al. [6] study) ionization sources.
The investigators reported four areas within the plasma
rotein map corresponding to isoforms of alpha-1-
ntitrypsin (AAT), fibrinogen gamma chain (FGG), apoli-
oprotein A-I and gamma-immunoglobulin heavy chains
hat changed with AMI and UA. One of these proteins—
AT—is a strong inhibitor of several proteolytic enzymes,
nd low AAT levels have been suggested to play a role in
therogenesis (9). The authors found that AAT isoform 1
as absent in the plasma of patients with AMI and UA,
ith more subtle changes in the expression of isoforms 5, 6,
nd 7, which differed between AMI and UA, suggesting a
nique biosignature existed for each condition. Although it
s tempting to speculate on a link between these changes and
athophysiologic mechanisms, it should be noted that these
ndings merely suggest an association between ACS and
AT, and more definitive proof will await larger prospec-
ive studies combined with mechanistic data from animal-
ased experiments. Likewise, although statistically signifi-
ant, all the differences, except with AAT isoform I, were
ery modest. Given the fact that gender, age, race, differ-
nces in medication use, and co-morbid conditions can
ffect the proteome (10), the choice of control group is
rucial. A major methodologic problem plaguing similar
enetic studies is the selection of controls, which may be an
mportant source of bias. The choice of control groups in
uture studies will need to be closely scrutinized if the
ndings generated are to lead to useful pathophysiologic
nsights or, alternatively, if they are to be useful as clinical
creening tools. Nonetheless, the report by Matteos-Cáceres ot al. (6) is potentially an important study, as there is a
aucity of data in the literature regarding proteomic changes
ssociated with coronary syndromes.
This report likely represents the first of many in this field,
s there is certainly additional important information that
an be generated on ACS by similar studies. As recognized
y the authors, all electrophoretic techniques are limited by
tain sensitivity and dynamic range of protein expression
nd thus are not able to visualize all proteins. In response to
his limitation, the authors focused their analysis on regions
f overt difference between the control and diseased two-
imensional electrophoresis plasma maps, but this approach
oes not allow comprehensive coverage. Therefore, this
tudy would not identify potentially important changes in
roteins below this threshold, a limitation that can only be
vercome by repetitive, unbiased gel sampling. An advan-
age of this approach, however, is that by focusing on an
rea of marked alteration between the normal and diseased
atients, the authors increased their chances of identifying
roteins with altered function that are directly related to the
isease phenotype. Future studies that utilize cutting-edge
S techniques and equipment will undoubtedly generate
dditional information. Tandem MS approaches, aimed at
haracterizing protein modification, have the potential to
ield additional information on post-translational modifica-
ions, cleavage events, and other protein alterations that are,
n themselves, biomarkers. Likewise, despite the ability of
el staining to give a relative estimation of protein abun-
ance, true MS quantitation requires protein-labeling tech-
iques (e.g., isotope-coded affinity tagging). The imple-
entation of these quantitative techniques to clinical
roteomic investigations will increase the applicability of the
ndings to diagnosis and care.
As these sophisticated proteomic markers/signatures
or coronary syndromes and other diseases continue to
evelop, the challenge will lie in translating the informa-
ion gained from these screens into clinically useful
iagnostic tests or therapeutic interventions. Although
S-based signatures can be easily generated in a reason-
bly outfitted proteomics laboratory, the time and exper-
ise to carry out these techniques, as well as the cost of the
ecessary equipment, are likely to prohibit the applica-
ion of these technologies “as is” in the clinical setting.
herefore, unless significant advances occur in the field
f MS in the near future, assays will need to be developed
nce a relevant biosignature is identified, which are both
ore sensitive and inexpensive, such as targeted immu-
oassays. Likewise, if identification of clinically useful
iosignatures is to occur, future studies will need to
ddress current limitations with quantitation. It will be
ssential that investigations deliver truly quantitative
nformation on protein expression or modification
hanges associated with coronary syndromes or other
ardiovascular diseases. Moreover, qualitative and quan-
itative changes must be analyzed on much larger cohorts
f patients with carefully chosen control populations.
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Editorial Comment October 19, 2004:1584–6hese studies will likely require more extensive, perhaps
ulti-institutional clinical trials to orchestrate collection
f plasma (or other body fluid) samples and to coordinate
ith scientists with expertise in proteomics who can
valuate these end points. Proteomics holds substantial
romise to improve the diagnosis and care of patients, but
ow both basic science and clinical investigators deal
ith the considerable challenges will determine whether
his promise is to be delivered.
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